Risk factors for pre-term birth in a Canadian cohort of HIV-positive women: role of ritonavir boosting?

Abstract

Background

The risk of pre-term birth (PTB) associated with the use of protease inhibitors (PIs) during pregnancy remains a subject of debate. Recent data suggest that ritonavir boosting of PIs may play a specific role in the initiation of PTB, through an effect on the maternal–fetal adrenal axis. The primary objective of this study is to compare the risk of PTB among women treated with boosted PI versus non-boosted PIs during pregnancy.

Methods

Between 1988 and 2011, 705 HIV-positive women were enrolled into the Centre Maternel et Infantile sur le SIDA mother–infant cohort at Centre Hospitalier Universitaire Sainte-Justine in Montreal, Canada. Inclusion criteria for the study were: 1) attendance at a minimum of two antenatal obstetric visits and 2) singleton live birth, at 24 weeks gestational or older. The association between PTB (defined as delivery at <37 weeks gestational age), antiretroviral drug exposure and maternal risk factors was assessed retrospectively using logistic regression.

Results

A total of 525 mother–infant pairs were included in the analysis. Among them, PI-based combination anti-retroviral therapy was used in 37.4%, boosted PI based in 24.4%, non-nucleoside reverse transcriptase inhibitor (NNRTI) or nucleoside reverse transcriptase inhibitor based in 28.1%, and no treatment was given in 10.0% of cases. Overall, 13.5% of women experienced PTB. Among women treated with antiretroviral therapy, the risk of PTB was significantly higher among women who received boosted versus non-boosted PI (OR 2.01, 95% CI 1.02–3.97). This remained significant after adjusting for maternal age, delivery CD4 count, hepatitis C co-infection, history of previous PTB, and parity (aOR 2.17, 95% CI 1.05–4.51). There was no increased risk of PTB with the use of unboosted PIs as compared to NNRTI- or NRTI-based regimens.

Conclusion

While previous studies on the association between PTB and PI use have generally considered all PIs the same, our results would indicate a possible role of ritonavir boosting as a risk factor for PTB. Further work is needed to understand the pathophysiologic mechanisms involved, and to identify the safest ARV regimens to be used in pregnancy.

References European Collaborative Study; Swiss Mother and Child HIV Cohort Study. Combination antiretroviral therapy and duration of pregnancy. AIDS. 2000; 14(18):2913–20. Thorne C, Patel D, Newell ML. Increased risk of adverse pregnancy outcomes in HIV-infected women treated with highly active antiretroviral therapy in Europe. AIDS. 2004;18(17):2337–9. Townsend CL, Cortina-Borja M, Peckham CS, Tookey PA. Antiretroviral therapy and premature delivery in diagnosed HIV-infected women in the United Kingdom and Ireland. AIDS. 2007;21(8):1019–26. Grosch-Woerner I, Puch K, Maier RF, Niehues T, Notheis G, Patel D, et al. Increased rate of prematurity associated with antenatal antiretroviral therapy in a German/Austrian cohort of HIV-1-infected women. HIV Med. 2008;9(1): 6–13. Tuomala RE, Watts DH, Li D, Vajaranant M, Pitt J, Hammill H, et al. Improved obstetric outcomes and few maternal toxicities are associated with antiretroviral therapy, including highly active antiretroviral therapy during pregnancy. J Acquir Immune Defic Syndr. 2005;38(4):449–73. Dola CP, Khan R, DeNicola N, Amirgholami M, Benjamin T, Bhuiyan A, et al. Combination antiretroviral therapy with protease inhibitors in HIV-infected pregnancy. J Perinat Med. 2011;40(1):51–5. Patel K, Shapiro DE, Brogly SB, Livingston EG, Stek AM, Bardeguez AD, et al. Prenatal protease inhibitor use and risk of preterm birth among HIV-infected women initiating antiretroviral drugs during pregnancy. J Infect Dis. 2010; 201(7):1035–44. Cotter AM, Garcia AG, Duthely ML, Luke B, O'Sullivan MJ. Is antiretroviral therapy during pregnancy associated with an increased risk of preterm delivery, low birth weight, or stillbirth? J Infect Dis. 2006;193(9):1195–201. Watts DH, Williams PL, Kacanek D, Griner R, Rich K, Hazra R, et al. Combination antiretroviral use and preterm birth. J Infect Dis. 2013;207(4): 612–21. Kourtis AP, Schmid CH, Jamieson DJ, Lau J. Use of antiretroviral therapy in pregnant HIV-infected women and the risk of premature delivery: a meta-analysis. AIDS. 2007;21(5):607–15. Van der Merwe K, Hoffman R, Black V, Chersich M, Coovadia A, Rees H. Birth outcomes in South African women receiving highly active antiretroviral therapy: a retrospective observational study. J Int AIDS Soc. 2011;14:42. Machado ES, Hofer CB, Costa TT, Nogueira SA, Oliveira RH, Abreu TF, et al. Pregnancy outcome in women infected with HIV-1 receiving combination antiretroviral therapy before versus after conception. Sex Transm Infect. 2009;85(2):82–7. Ravizza M, Martinelli P, Bucceri A, Fiore S, Alberico S, Tamburrini E, et al. Treatment with protease inhibitors and coinfection with hepatitis C virus are independent predictors of preterm delivery in HIV-infected pregnant women. J Infect Dis. 2007;195(6):913–14; author reply 916–17. Panel on Treatment of HIV-Infected Pregnant Women and Prevention of Perinatal Transmission. Recommendations for use of antiretroviral drugs in pregnant HIV-1-infected women for maternal health and interventions to reduce perinatal HIV transmission in the United States. 2012 [cited 2013 Aug 22]. Available from: http://aidsinfo.nih.gov/contentfiles/lvguidelines/PerinatalGL.pdf Public Health Service Taskforce: Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-1 Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV-1 Transmission in the United States. 2006 Oct 12 [cited 2013 Aug 22]; 1–65. Available from: http://aidsinfo.nih.gov/contentfiles/PerinatalGL DHHS Perinatal Panel Notice on Nelfinavir FDA-Pfizer Letter, September 11, 2007. [cited 2013 Aug 22]. Available from: http://aidsinfo.nih.gov/contentfiles/upload/PeriNFVNotice1.pdf Public Health Service Task Force: Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-1-Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV Transmission in the United States. 2007 [cited 2013 Aug 22]. Available from: http://aidsinfo.nih.gov/ContentFiles/PerinatalGL02112007901.pdf Public Health Service Task Force: Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-1-Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV Transmission in the United States. 2008 [cited 2013 Aug 22]. Available from: http://aidsinfo.nih.gov/contentfiles/PerinatalGL001020.pdf Baroncelli S, Tamburrini E, Ravizza M, Dalzero S, Tibaldi C, Ferrazzi E, et al. Antiviral treatment in pregnancy: a six-year prospective on recent trends in prescription patterns, viral load suppression, and pregnancy outcomes. AIDS Patient Care STDS. 2009;23(7):513–20. Andany N, Loutfy MR. HIV protease inhibitors in pregnancy: pharmacology and clinical use. Drugs. 2013;73(3):229–47. Granfors MT, Wang JS, Kajosaari LI, Laitila J, Neuvonen PJ, Backman JT. Differential inhibition of cytochrome P450 3A4, 3A5 and 3A7 by five human immunodeficiency virus (HIV) protease inhibitors in vitro. Basic Clin Pharmacol Toxicol. 2006;98(1):79–85. Beshay VE, Carr BR, Rainey WE. The human fetal adrenal gland, corticotropin-releasing hormone, and parturition. Semin Reprod Med. 2007; 25(1):14–20. Simon A, Warszawski J, Kariyawasam D, Le Chenadec J, Benhammou V, Czernichow P, et al. Association of prenatal and postnatal exposure to V-ritonavir and adrenal dysfunction among uninfected infants of HIV-infected mothers. JAMA. 2011;306(1):70–8. Lopez M, Figueras D, Hernandez S, Lonca M, Garcia R, Palacio M, et al. Association of HIV infection with spontanous and iatrogneic preterm delivery. AIDS. 2012;26(1):37–43. Sibiude J, Warszawski J, Tubiana R, Dollfus C, Faye A, Rouzioux C, et al. Premature delivery in HIV-infected women starting protease inhibitor therapy during pregnancy: role of the ritonavir boost? Clin Infect Dis. 2012;54(9): 1348–60. Powis KM, Kitch D, Ogwu A, Hughes MD, Lockman S, Leidner J, et al. Increased risk of preterm delivery among HIV-infected women randomized to protease versus nucleoside reverse transcriptase inhibitor-based CART during pregnancy. J Infect Dis. 2011;204(4):506–14. Carceller A, Ferreira EM, Alloul S, Lapointe N. Lack of effect on prematurity, birth weight and infant growth from exposure to protease inhibitors in utero and after birth. Pharmacotherapy. 2009;29(111):1289–96. Morris AB, Cu-Uvin S, Harwekk JI, Garb J, Zorrilla C, Vajaranant M, et al. Multicenter review of protease inhibitors in 89 pregnancies. J Aquir Immune Defic Syndr. 2000;25:306–11. Schulte J, Dominguez K, Sukalac T, Bohannon B, Fowler MG Pediatric Spectrum of HIV Disease Consortium. Declines in low birth weight and preterm birth among infants who were born to HIV-infected women during an era of increased use of maternal antiretroviral drugs: Pediatric Spectrum of HIV Disease, 1989–2004. Pediatrics. 2007;119(4):e900–6. Papp E, Mohammadi H, Loutfy MR, Yudin MH, Murphy KE, Walmsley SL, et al. HIV protease inhibitor use during pregnancy is associated with decreased progesterone levels, suggesting a potential mechanism contributing to fetal growth restriction. J Infec Dis. 2015;211(1):10–8. Wimalasundera RC, Larbalestier N, Smith JH, de Ruiter A, McG Thom SA, et al. Pre-eclampsia, antiretroviral therapy, and immune reconstitution. Lancet. 2002;360(9340):1152–4. Brophy C, Kakkar F, Sauve L, Lee T, Bitnun A, Alimenti A, et al. Transition of Youth Living with HIV from Pediatric to Adult Care in Canada: Past, Present, and Future. Canadian Journal of Infectious Diseases and Medical Microbiology. 2014;25(Suppl A):63A. Antoniou T, Zagorski B, Macdonald EM, Bayoumi AM, Raboud J, Brophy J, et al. Trends in live births and adverse neonatal outcomes among HIV-positive women in Ontario, Canada, 2002–2009: a descriptive population-based study. Int J STD AIDS. 2014;25(13):960–6. Chen JY, Ribaudo HJ, Souda S, Parekh N, Ogwu A, Lockman S, et al. Highly active antiretroviral therapy and adverse birth outcomes among HIV-infected women in Botswana. J Infect Dis. 2012;206(11):1695–705. Ezechi OC, David AN, Gab-Okafor CV, Ohwodo H, Oladele DA, Kalejaiye OO, et al. Incidence of and socio-biologic risk factors for spontaneous preterm birth in HIV positive Nigerian women. BMC Pregnancy Childbirth. 2012;12:93. Warszawski J, Le Chenadec J, Mandelbrot L, Faye A, Dolfus X, Tubiana R, et al. Infant mortality among HIV-uninfected children during the HAART era in France – ANRS French perinatal cohort. 19th Conference on Retroviruses and Opportunistic Infections (CROI); 2012 Mar 5–8, Seattle, WA. Poster #1032.